Media Highlights and Announcements
Bio WorldNovember 30, 2021
Artrya lists on ASX in AU$40M IPO to advance coronary artery disease AI software
Medtech newcomer Artrya Ltd. listed on the Australian Securities Exchange (ASX) in an AU$40 million (US$28.6 million) initial public offering.
The Motley FoolNovember 29, 2021
New artificial intelligence ASX share rockets 13% on debut
Move over Appen, the new AI player in town went gangbusters on its first day as a public company.
November 26, 2021
Artrya gets to the heart of AI with ASX listing, $40 million IPO
Fresh from its ASX debut, AYA’s mission is simple: it’s out to more accurately and less invasively detect signs of heart disease with the power of artificial intelligence (AI).
Business NewsNovember 26, 2021
Artrya rises on ASX debut
Local medtech Artya has listed on the stock exchange, having earlier raised $40 million through an IPO to help commercialise its cardiac imaging software.
The Market HeraldNovember 26, 2021
Cardiac imaging software company Artrya (ASX:AYA) up on public debut
Artrya (AYA), an artificial intelligence medical technology business, has started trading on the ASX after the successful completion of its initial public offering (IPO).
StockheadNovember 26, 2021
How did this week’s five IPOs perform?
The medical technology company listed today after raising $40 million at $1.35. Its share price is up ~13% to $1.52.
November 24, 2021
Australian AI Company Artrya Announces Major UK Commercialisation Partnership with Eversana
AI medical technology company Artrya Limited is announcing its partnership with leading global commercial services provider EVERSANA Life Sciences LLC.
November 15, 2021
Boreham’s Crucible: Breaking down ASX aspirant Artrya’s AI heart disease warning system
In this Stockhead article, Tim Boreham dives into Artrya as a company and shares his thoughts in the current $100M market valuation. He also speaks on Artya’s recent accomplishments as well as goals in the months and years to come.
November 09, 2021
UK preferred supplier status for Australian AI company Artrya
Artrya has been accepted onto the UK National Health Service Shared Business Services (NHS SBS) Framework as a supplier of artificial intelligence software and platforms.
November 09, 2021
How to invest in the Artrya IPO
With the latest capital raise once again oversubscribed, Artrya has worked diligently to accommodate as many applications as possible.